EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of mirabegron after posterior urethral valve ablation

Omar Mohamed, Mohamed Ahmed Hassan El-Gelany, Atef Fathi, Ahmad Abolyosr

Urology Annals · 2026-10 · 18 (4) · 355-360

DOI: 10.4103/ua.ua_129_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urology Annals, online erschienen am 30.10.2026. Verfasst von Omar Mohamed und 3 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Valve bladder syndrome is a persistent bladder dysfunction after posterior urethral valve (PUV) ablation, causing poor bladder compliance and possible renal deterioration. Mirabegron may improve bladder function with fewer side effects than anticholinergic therapy, but evidence after PUV ablation is limited.

Aim

To evaluate efficacy and safety of mirabegron after PUV ablation. Patients and Methods: This cross-sectional study included 15 children older than 3 years who underwent PUV ablation and received mirabegron (0.5–1 mg/kg/day). Patients with residual valves, previous urinary diversion, or associated neurogenic bladder were excluded. Baseline assessment included clinical examination, urine analysis, serum creatinine, renal/bladder ultrasound, voiding cystourethrogram, and SWRD score evaluation. Patients were followed for 6 months with clinical, laboratory, and radiological monitoring to evaluate treatment efficacy and safety.

Results

The mean age was 7.21 ± 2.93 years, with mean weight 19.55 ± 7.69 kg and height 115.89 ± 19.27 cm. After 6 months of mirabegron therapy, febrile urinary tract infection episodes decreased significantly ( P = 0.0223), pyuria improved ( P = 0.0352) and serum creatinine decreased ( P < 0.0001). Improvement was observed in vesicoureteral reflux (9 renal units, 30%) and hydronephrosis (13 renal units, 43.3%) although changes in grades were not statistically significant. Bladder shape and total SWRD scores significantly improved ( P = 0.0335 and P = 0.0302). Adverse effects were reported in 2 patients (13.33%), including constipation and headache.

Conclusion

Mirabegron appears to be a safe and effective option for bladder dysfunction after PUV ablation, improving urinary symptoms, renal parameters, and bladder status. Larger studies with longer follow-up are needed to confirm long-term benefits.

Zitieren

APA

Mohamed, O., El-Gelany, M. A. H., Fathi, A., & Abolyosr, A. (2026). Efficacy and safety of mirabegron after posterior urethral valve ablation. Urology Annals, 18(4), 355-360. https://doi.org/10.4103/ua.ua_129_26

Vancouver

Mohamed O, El-Gelany MAH, Fathi A, Abolyosr A. Efficacy and safety of mirabegron after posterior urethral valve ablation. Urology Annals. 2026;18(4):355-360. doi:10.4103/ua.ua_129_26

BibTeX
@article{Mohamed2026,
  author = {Mohamed, Omar and El-Gelany, Mohamed Ahmed Hassan and Fathi, Atef and Abolyosr, Ahmad},
  title = {Efficacy and safety of mirabegron after posterior urethral valve ablation},
  journal = {Urology Annals},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {355--360},
  doi = {10.4103/ua.ua_129_26}
}
Kostenlos starten →